Concepedia

Vanitha Sekar

VS

Statistics

Publications

26

Citations

1.8K

H-Index

21

Active since

2002

Affiliations

Janssen (United States)(Current)

Janssen (Belgium)

Goethe University Frankfurt

Janssen (Netherlands)

University Hospital Leipzig

Vanitha Sekar is an author at Janssen (United States) specializing in pharmacology, clinical pharmacology, and antiviral therapy.

Publications per year

2002–2013

26

Publications

26

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

Michael Fried, Gregory J. Dore, Robert Flisiak et al. · Hepatology · 2013 · 271 citations · Full text

, , +17

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

Anthony Mills, Mark Nelson, Dushyantha Jayaweera et al. · AIDS · 2009 · 266 citations

, , +17

Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial

Stefan Zeuzem, Thomas Berg, Edward Gane et al. · Gastroenterology · 2013 · 235 citations · Full text

, , +12

Darunavir: Pharmacokinetics and Drug Interactions

David Back, Vanitha Sekar, Richard M. W. Hoetelmans · Antiviral Therapy · 2008 · 122 citations · Full text

, , +17

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study

Christophe Moreno, Thomas Berg, Tawesak Tanwandee et al. · Journal of Hepatology · 2012 · 105 citations · Full text

, , +17

1–5 of 26